DE3662265D1 - Irreversible dopamine-b-hydroxylase inhibitors - Google Patents

Irreversible dopamine-b-hydroxylase inhibitors

Info

Publication number
DE3662265D1
DE3662265D1 DE8686306923T DE3662265T DE3662265D1 DE 3662265 D1 DE3662265 D1 DE 3662265D1 DE 8686306923 T DE8686306923 T DE 8686306923T DE 3662265 T DE3662265 T DE 3662265T DE 3662265 D1 DE3662265 D1 DE 3662265D1
Authority
DE
Germany
Prior art keywords
dopamine
irreversible
hydroxylase inhibitors
preparation
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8686306923T
Other languages
English (en)
Inventor
Pamela Anne Chambers
James Simpson Frazee
Carl Kaiser
Lawrence Ivan Kruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE3662265D1 publication Critical patent/DE3662265D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8686306923T 1985-09-09 1986-09-08 Irreversible dopamine-b-hydroxylase inhibitors Expired DE3662265D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/773,694 US4760089A (en) 1985-09-09 1985-09-09 Irreversible dopamine-β-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
DE3662265D1 true DE3662265D1 (en) 1989-04-13

Family

ID=25099026

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686306923T Expired DE3662265D1 (en) 1985-09-09 1986-09-08 Irreversible dopamine-b-hydroxylase inhibitors

Country Status (11)

Country Link
US (1) US4760089A (de)
EP (1) EP0219961B1 (de)
JP (1) JPS6261960A (de)
AT (1) ATE41146T1 (de)
AU (1) AU595232B2 (de)
DE (1) DE3662265D1 (de)
DK (1) DK421586A (de)
ES (1) ES2001775A6 (de)
GR (1) GR862290B (de)
PT (1) PT83316B (de)
ZA (1) ZA866808B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
MTP1031B (en) * 1987-12-24 1990-10-04 Orion Yhtymae Oy New use of cathecol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
EP1737809B1 (de) * 2004-02-27 2013-09-18 Amgen, Inc Verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung bei der behandlung von stoffwechselstörungen
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) * 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
WO2007106469A2 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
US7687526B2 (en) * 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CA2662305C (en) * 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
JP2010524932A (ja) * 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸ｇｐｒ４０調節物質
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
CA2716352C (en) * 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757031C2 (de) * 1976-12-27 1981-11-26 Agency Of Industrial Science And Technology Verfahren zur Herstellung von Aldehyden und/oder Alkoholen aus einem Toluolderivat mit Ätherbindungen
DE2950608A1 (de) * 1978-12-29 1980-07-10 Chinoin Gyogyszer Es Vegyeszet Verfahren zur herstellung von 2-(3-phenoxy-phenyl)-propionsaeure
DE3144150A1 (de) * 1981-04-10 1982-12-09 Basf Ag, 6700 Ludwigshafen (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel
US4496757A (en) * 1981-11-05 1985-01-29 Ciba-Geigy Corporation Ultraviolet-absorbing stabilizers substituted an aliphatic hydroxyl group
US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors

Also Published As

Publication number Publication date
PT83316A (en) 1986-10-01
PT83316B (en) 1988-10-07
ATE41146T1 (de) 1989-03-15
EP0219961B1 (de) 1989-03-08
GR862290B (en) 1987-01-02
EP0219961A1 (de) 1987-04-29
AU6216886A (en) 1987-03-12
DK421586D0 (da) 1986-09-03
ZA866808B (en) 1987-08-26
DK421586A (da) 1987-03-10
JPS6261960A (ja) 1987-03-18
ES2001775A6 (es) 1988-06-16
US4760089A (en) 1988-07-26
AU595232B2 (en) 1990-03-29

Similar Documents

Publication Publication Date Title
MY100343A (en) Amide derivative and external medicament comprising same
PH23847A (en) Polypeptide
DE3662265D1 (en) Irreversible dopamine-b-hydroxylase inhibitors
ES8601915A1 (es) Un procedimiento para preparar derivados de piridazinona
AU587258B2 (en) N-substituted-4-hydroxy-2-oxopyrrolidine derivatives
ES8609286A1 (es) Un metodo para preparar un compuesto de morfolinol
NO850580L (no) Isoksazol-derivater, fremgangsmaate til deres fremstilling, legemidler inneholdende disse forbindelser
IL75978A0 (en) Isoquinoline derivatives,their preparation and pharmaceutical compositions containing them
ES8407009A1 (es) Un procedimiento para preparar -15-desoxiespergualina.
ES8802612A1 (es) Procedimiento para preparar derivados de benzisoselenazolilo
EP0187711A3 (en) Octahydroindolizine compounds useful as analgesics
GR850107B (de)
GR850484B (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee